subscribeSubscribe
FDA Confirms Paragraph IV Patent Litigation for Fedratinib Hydrochloride

FDA Confirms Paragraph IV Patent Litigation for Fedratinib Hydrochloride
FDA
21 Sep 2023
Share Share
NICE recommends Inrebic for rare blood cancer

NICE recommends Inrebic for rare blood cancer
PHARMATIMES
19 Nov 2021
Share Share
BMS`s Receives Positive CHMP Opinion for Inrebic® (fedratinib)

BMS`s Receives Positive CHMP Opinion for Inrebic® (fedratinib)
BUSINESSWIRE
11 Dec 2020
Share Share
Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib)

Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib)
BUSINESSWIRE
11 Dec 2020
Share Share
Health Canada Approves INREBIC® (fedratinib), First New Treatment in Nearly

Health Canada Approves INREBIC® (fedratinib), First New Treatment in Nearly
BIOSPACE
21 Sep 2020
Share Share
Celgene`s Reblozyl faces FDA committee for myelodysplastic syndromes

Celgene`s Reblozyl faces FDA committee for myelodysplastic syndromes
K. Blankenship  FIERCE PHARMA
03 Dec 2019
Share Share
FDA Action Alert: Celgene, Xeris and Ardelyx

FDA Action Alert: Celgene, Xeris and Ardelyx
Mark Terry BIOSPACE
04 Sep 2019
Share Share
First bone marrow disorder treatment approved by the FDA after nearly a decade

First bone marrow disorder treatment approved by the FDA after nearly a decade
Vassia Barba IN-PHARMATECHNOLOGIST
21 Aug 2019
Share Share
FDA approves novel device to treat idiopathic scoliosis

FDA approves novel device to treat idiopathic scoliosis
BIOSPECTRUMASIA
19 Aug 2019
Share Share
Celgene`s v Inrebic receives USFDA approval to treat patients with myelofibrosis

Celgene`s v Inrebic receives USFDA approval to treat patients with myelofibrosis
PHARMABIZ
19 Aug 2019
Share Share